3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Oxaliplatin
10
Gemcitabine
8
Cisplatin
7
Hepatectomy
6
Fluorouracil
6
Radiofrequency Ablation
5
Liver Transplantation
5
Irinotecan
5
Capecitabine
5
lenvatinib
4
Paclitaxel
4
Neoadjuvant Therapy
4
Folfox protocol
4
Cetuximab
4
Aspirin
4
tislelizumab
3
Surgical Procedures, Operative
3
Nivolumab
3
Carboplatin
3
titanium silicide
2
durvalumab
2
apatinib
2
Trastuzumab
2
S 1 (combination)
2
Leucovorin
2
Lamivudine
2
Introns
2
Ethiodized Oil
2
Drug Therapy
2
DNA, Mitochondrial
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tinostamustine
×
Gastrointestinal
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts